Open Beta
MetriLume

US marketsTCRX

SEC-sourced researchBeta

TCRX

TScan Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001783328
Exchange
Nasdaq
Business activity
— · SIC 2836
Financial inputs
6/6
Filing date
Oct 2, 2026
SEC registry record
Operating company

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 2,816,000.0000 USD; December 2025: 10,325,000.0000 USD10.3M USD0 USD0December 2024December 2025
TCRX · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20242,816,000.0000Mar 4, 2026
December 202510,325,000.0000Mar 4, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202510,325,000.0000-129,766,000.0000-135,319,000.0000228,789,000.0000105,666,000.0000Mar 4, 2026
December 20242,816,000.0000-127,499,000.0000-110,822,000.0000371,118,000.0000130,148,000.0000Mar 4, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$10.33MDecember 2025Mar 4, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$2.82MDecember 2024Mar 4, 202610-K
Net incomeNetIncomeLoss-$129.77MDecember 2025Mar 4, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$135.32MDecember 2025Mar 4, 202610-K
Total assetsAssets$228.79MDecember 2025Mar 4, 202610-K
Total liabilitiesLiabilities$105.67MDecember 2025Mar 4, 202610-K

New filings

Explore methodology ↗